
  
    
      
        
        We_PRP appreciate_VBP the_DT note_NN from_IN Drs_NNP ._. Koudinov_NNP and_CC Berezov_NNP [_NN 1_CD ]_NN ._. In_IN our_PRP$ opinion_NN ,_, no_DT model_NN has_VBZ
        yet_RB been_VBN presented_VBN that_IN plausibly_RB accounts_VBZ for_IN all_PDT the_DT data_NN on_IN statins_NNS ,_, cholesterol_NN ,_,
        amyloid-ß_JJ protein_NN (_( Aß_NNP )_) ,_, and_CC Alzheimer_NNP disease_NN ._. In_IN our_PRP$ paper_NN [_NN 2_CD ]_NN ,_, we_PRP present_JJ evidence_NN that_IN
        the_DT isoprenoid_NN pathway_NN contributes_VBZ to_TO statin-activated_JJ shedding_NN of_IN the_DT APP_NNP ectodomain_NN in_IN
        cultured_JJ cells_NNS ._. We_PRP do_VBP not_RB yet_RB know_VB which_WDT (_( if_IN any_DT )_) other_JJ “ cholesterol-related_JJ” Alzheimer_NNP
        phenomena_NNS are_VBP also_RB attributable_JJ to_TO modulation_NN of_IN isoprenoids_NNS ,_, Rho_NNP ,_, or_CC ROCK_NNP ._.
        Previously_RB ,_, conventional_JJ wisdom_NN held_VBN that_IN Aß_NNP load_NN and_CC hypercholesterolemia_NN were_VBD directly_RB
        related_VBN ,_, based_VBN on_IN observations_NNS that_IN high-fat_JJ diet_NN aggravated_VBD amyloid_NN pathology_NN in_IN
        plaque-forming_JJ mice_NNS [_NN 3_CD ,_, 4_CD ,_, 5_CD ]_NN ._. More_RBR recently_RB ,_, however_RB ,_, the_DT formulation_NN that_IN statins_NNS act_VBP
        simply_RB via_IN cholesterol-lowering_JJ fails_VBZ to_TO account_VB for_IN several_JJ observations_NNS that_WDT cannot_NN
        immediately_RB be_VB reconciled_JJ ,_, either_CC with_IN the_DT original_JJ “ dogma_NN” or_CC with_IN each_DT other_JJ ._.
        First_LS ,_, Fagan_NNP et_CC al_NN ._. [_NN 6_CD ]_NN questioned_VBD the_DT role_NN of_IN cholesterol_NN as_IN the_DT final_JJ common_JJ pathway_NN
        in_IN Aß_NNP load_NN specification_NN ,_, since_RB ,_, in_IN their_PRP$ experiments_NNS ,_, low_JJ cholesterol_NN per_IN se_FW apparently_RB
        had_VBD no_DT impact_NN on_IN brain_NN Aß_NNP load_NN in_IN plaque-forming_JJ transgenic_JJ mice_NNS ._. Then_RB ,_, equally_RB puzzling_JJ
        pharmacological_JJ data_NNS emerged_VBD ._. Atorvastatin_NNP was_VBD shown_VBN to_TO lower_JJR brain_NN amyloid_NN load_NN and_CC Aß_NNP
        levels_NNS ,_, but_CC brain_NN cholesterol_NN levels_NNS were_VBD unaffected_JJ by_IN the_DT drug_NN [_NN 7_CD ]_NN ._. In_IN an_DT apparent_JJ
        complete_JJ contradiction_NN with_IN the_DT original_JJ observations_NNS ,_, now_RB ,_, some_DT investigators_NNS have_VBP been_VBN
        able_JJ to_TO devise_VB circumstances_NNS under_IN which_WDT there_EX is_VBZ an_DT inverse_NN relationship_NN between_IN
        cholesterol_NN and_CC Aß_NNP ,_, with_IN low_JJ neuronal_NN cholesterol_NN increasing_VBG Aß_NNP generation_NN [_NN 8_CD ]_NN ,_, and_CC vice_NN
        versa_RB [_NN 9_CD ]_NN ._. These_DT newer_JJR observations_NNS are_VBP unexpected_JJ and_CC extremely_RB puzzling_JJ ,_, and_CC no_DT
        comprehensive_JJ explanation_NN has_VBZ yet_RB emerged_VBN ._.
        For_IN those_DT readers_NNS seeking_VBG an_DT update_NN on_IN this_DT challenging_VBG area_NN ,_, we_PRP would_MD direct_VB your_PRP$
        attention_NN to_TO the_DT Alzheimer_NNP Research_NNP Forum_NNP Web_NNP page_NN
        (_( http_NN :_: /_NN /_NN www_NN ._. alzforum_NN ._. org_NN /_NN new_JJ /_NN detailprint_NN ._. asp_NN ?_. id_NN =_SYM 1135_CD )_) ,_, where_WRB you_PRP will_MD find_VB an_DT excellent_JJ
        review_NN of_IN the_DT literature_NN as_RB well_RB as_IN a_DT series_NN of_IN evaluations_NNS of_IN how_WRB our_PRP$ data_NNS fit_VBP into_IN
        existing_VBG scenarios_NNS and_CC models_NNS regarding_VBG cholesterol_NN ,_, statins_NNS ,_, cerebral_JJ amyloidosis_NNS ,_, and_CC the_DT
        cognitive_JJ failure_NN of_IN Alzheimer_NNP disease_NN ._.
      
    
  
